Certolizumab Pegol in Combination with Methotrexate in DMARD-Naive Patients with Active, Severe, Progressive Rheumatoid Arthritis: Results from a Randomized, Double-Blind, Controlled Phase 3 Study

被引：0

作者：

Weinblatt, Michael ^{[1
]}

Bingham, Clifton ^{[2
]}

Burmester, Gerd ^{[3
]}

Bykerk, V. P. ^{[4
]}

Furst, Daniel E. ^{[5
]}

Mariette, Xavier ^{[6
]}

van der Heijde, Desiree ^{[7
]}

Tatla, Daljit ^{[8
]}

Arendt, Catherine ^{[9
]}

Mountian, Irina ^{[10
]}

VanLunen, Brenda ^{[11
]}

Emery, Paul ^{[12
]}

机构：

[1] Brigham & Womens Hosp, Rheumatol Immunol & Allergy, Boston, MA 02115 USA

[2] Johns Hopkins Univ, Baltimore, MD USA

[3] Charite, Dept Rheumatol & Clin Immunol, D-13353 Berlin, Germany

[4] Hosp Special Surg, Rheumatol, New York, NY 10021 USA

[5] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA

[6] Univ Paris 11, Hop Univ Paris Sud, AP HP, Paris, France

[7] State Univ Limburg Hosp, NL-6201 BX Maastricht, Netherlands

[8] UCB Pharma, Raleigh, NC USA

[9] UCB Pharma, Global Med Affairs, Brussels, Belgium

[10] UCB Pharma, Brussels, Belgium

[11] UCB Pharma, Raleigh, NC USA

[12] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

来源：

ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

968

引用

页数：3

共 50 条

[31] Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR
Mazurov, V. I.
Nasonov, E. L.
Lila, A. M.
Korolev, M. A.
Prystrom, A. M.
Kundzer, E. V.
Soroka, N. F.
Kastanayan, A. A.
Povarova, T. V.
Plaksina, T. V.
Antipova, O. V.
Krechikova, D. G.
Smakotina, S. A.
Tciupa, O. A.
Puntus, E. V.
Raskina, T. A.
Shilova, L. N.
Kropotina, T. V.
Nesmeyanova, O. B.
Popova, T. A.
Vinogradova, I. B.
Dokukina, E. A.
Plotnikova, A. V.
Pukhtinskaia, P. S.
Zinkina-Orikhan, A. V.
Linkova, Yu. N.
Eremeeva, A. V.
Lutckii, A. A.
[J]. DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2024,
[32] Vaccine Responses in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial
Kivitz, Alan J.
Schechtman, Joy
Texter, Michele
Fichtner, Andreas
de Longueville, Marc
Chartash, Elliot K.
[J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (04) : 648 - 657
[33] Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
Smolen, J. S.
Emery, P.
Ferraccioli, G. F.
Samborski, W.
Berenbaum, F.
Davies, O. R.
Koetse, W.
Purcaru, O.
Bennett, B.
Burkhardt, H.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (05) : 843 - 850
[34] Maintenance of Remission After Withdrawal of Etanercept or Methotrexate in Patients with Rheumatoid Arthritis in Sustained Remission on Combination Therapy: Results from a Randomized, Double-blind, Controlled Trial
Curtis, Jeffrey R.
Emery, Paul
Karis, Elaine
Haraoui, Boulos
Bykerk, Vivian
Yen, Priscilla
Kricorian, Gregory
Chung, James
[J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
[35] Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy
Hobbs, Kathryn
Deodhar, Atul
Wang, Brian
Bitman, Bojena
Nussbaum, Joyce
Chung, James
Collier, David H.
[J]. SPRINGERPLUS, 2015, 4 : 1 - 7
[36] OLOKIZUMAB IMPROVES PATIENT REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY METHOTREXATE: RESULTS FROM THE DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE III STUDY (CREDO-1)
Nasonov, E.
Ivanova, M.
Samsonov, M.
Tyabut, T.
Genovese, M. C.
Fatenejad, Saeed
Krechikova, Diana
Kuzkina, Sofia
Maslyansky, Alexey
Plaksina, Tatiana
Stanislav, Marina
Yakushin, Sergey
Zonova, Elena
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 300 - 301
[37] Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study
Weinblatt, Michael E.
Fleischmann, Roy
Huizinga, Tom W. J.
Emery, Paul
Pope, Janet
Massarotti, Elena M.
van Vollenhoven, Ronald F.
Wollenhaupt, Juergen
Bingham, Clifton O., III
Duncan, Ben
Goel, Niti
Davies, Owen R.
Dougados, Maxime
[J]. RHEUMATOLOGY, 2012, 51 (12) : 2204 - 2214
[38] PRTX-100 and Methotrexate in Patients With Active Rheumatoid Arthritis: A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study
Bernton, Edward
Gannon, William
Kramer, William
Kranz, Eduard
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (06): : 477 - 486
[39] Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis
Chen, Der-Yuan
Chou, Show-Jan
Hsieh, Tsu-Yi
Chen, Yi-Hsing
Chen, Hsin-Hua
Hsieh, Chia-Wei
Lan, Joung-Liang
[J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2009, 108 (04) : 310 - 319
[40] Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Fleischmann, Roy
Pangan, Aileen L.
Song, In-Ho
Mysler, Eduardo
Bessette, Louis
Peterfy, Charles
Durez, Patrick
Ostor, AndrewJ
Li, Yihan
Zhou, Yijie
Othman, Ahmed A.
Genovese, Mark C.
[J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71 (11) : 1788 - 1800

← 1 2 3 4 5 →